Thermo Fisher Completes Finnzymes Acquisition | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that it has completed its acquisition of Finnzymes for an undisclosed sum.

Espoo, Finland-based Finnzymes makes reagents, consumables, kits, and instruments for molecular biology applications. Its proprietary DNA polymerases, called Phire and Phusion, and high-speed miniaturized thermal cyclers will expand Thermo Fisher's portfolio of reagents and other consumables for the molecular biology research and diagnostics markets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.